Celltex Therapeutics Corporation and Steadman Philippon Research Institute (SPRI)have entered a clinical research agreement, which includes funding from Celltex for a clinical research project that will study adult adipose-derived Mesenchymal Stem Cells (MSCs) and their application for anti-aging.
In this world-class partnership, Celltex will provide human MSCs isolated from fat tissue that are IRB approved and patient consented for use by SPRI. The SPRI lab will conduct invitro research studies at its newly-renovated and highly-equipped Center for Regenerative Sports Medicine (CRSM) lab in Vail, CO.
After receiving MSCs from Celltex, the SPRI team will culture, expand and bank the cells to proceed with research including characterization of Celltex MSCs and their potential sub-populations to determine functional defects accumulated during aging of cells and stem cell senescence at the nuclear and protein expression levels. The SPRI team will also study signaling pathways involved in MSCs and their physio-biological properties under stress conditions, tested for proliferation and differentiation potentials with platelet rich plasma and/or bone marrow aspirate concentrates priming effect.
“We are proud to collaborate with SPRI to further our mission of using MSCs in ways that improve quality of life,” says Celltex CEO David G. Eller. “Through this partnership, we will uncover the incredible possibilities our own Mesenchymal Stem Cells have for anti-aging, wellness and overall health. The medical community continues to explore how stem cell therapy can transform health. SPRI has a unique and talented team that will characterize MSCs to study their impact on aging and age-related pathologies to explore potential solutions through regenerative medicine research and clinical translation.”
About Celltex Therapeutics Corporation
Celltex uses proprietary technology that isolates, multiplies and banks autologous (one’s own) adult mesenchymal stem cells (MSCs), to be used in regenerative therapy for injuries and chronic pain as well as a number of other conditions, including vascular, degenerative and autoimmune diseases. Celltex is registered with the FDA as an HCT/P establishment that multiplies human cells and cellular products. The Houston-based biotechnology company operates in a state-of-the-art laboratory compliant with Current Good Manufacturing Practice (cGMP) standards as recommended by the U.S. Food and Drug Administration (FDA) for the manufacturing of biological products. To learn more about Celltex, visit www.celltexbank.com
About Steadman Philippon Research Institute
The Steadman Philippon Research Institute is recognized globally for its pioneering research in osteoarthritis, healing, surgery, and injury prevention and rehabilitation. Since 1993 SPRI’s database (one of the largest in existence) has been collecting the patient information that has led to significant treatment advances in these areas.